ATE388964T1 - Modifizierter löslicher t-zellen-rezeptor - Google Patents

Modifizierter löslicher t-zellen-rezeptor

Info

Publication number
ATE388964T1
ATE388964T1 AT03815958T AT03815958T ATE388964T1 AT E388964 T1 ATE388964 T1 AT E388964T1 AT 03815958 T AT03815958 T AT 03815958T AT 03815958 T AT03815958 T AT 03815958T AT E388964 T1 ATE388964 T1 AT E388964T1
Authority
AT
Austria
Prior art keywords
tcr
cell receptor
chain
modified soluble
domain
Prior art date
Application number
AT03815958T
Other languages
English (en)
Inventor
Bent Jakobsen
Meir Glick
Original Assignee
Medigene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medigene Ltd filed Critical Medigene Ltd
Application granted granted Critical
Publication of ATE388964T1 publication Critical patent/ATE388964T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Jellies, Jams, And Syrups (AREA)
AT03815958T 2003-02-22 2003-07-09 Modifizierter löslicher t-zellen-rezeptor ATE388964T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0304068.0A GB0304068D0 (en) 2003-02-22 2003-02-22 Substances

Publications (1)

Publication Number Publication Date
ATE388964T1 true ATE388964T1 (de) 2008-03-15

Family

ID=9953480

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03815958T ATE388964T1 (de) 2003-02-22 2003-07-09 Modifizierter löslicher t-zellen-rezeptor

Country Status (12)

Country Link
US (1) US7666604B2 (de)
EP (1) EP1594896B1 (de)
JP (1) JP4478034B2 (de)
CN (1) CN100528897C (de)
AT (1) ATE388964T1 (de)
AU (1) AU2003254443B2 (de)
CA (1) CA2516702C (de)
DE (1) DE60319745T2 (de)
GB (1) GB0304068D0 (de)
NZ (1) NZ541596A (de)
WO (1) WO2004074322A1 (de)
ZA (1) ZA200506516B (de)

Families Citing this family (222)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6759243B2 (en) 1998-01-20 2004-07-06 Board Of Trustees Of The University Of Illinois High affinity TCR proteins and methods
EP1421115B1 (de) * 2001-08-31 2005-03-02 Avidex Limited Löslicher t zell rezeptor
GB0226227D0 (en) * 2002-11-09 2002-12-18 Avidex Ltd Receptors
US20060047435A1 (en) * 2004-08-24 2006-03-02 Ishikawa Muriel Y System and method related to augmenting an immune system
US20060047436A1 (en) * 2004-08-25 2006-03-02 Ishikawa Muriel Y System and method for magnifying an immune response
US20060122784A1 (en) * 2004-12-03 2006-06-08 Ishikawa Muriel Y System and method for augmenting a humoral immune response
US20060047434A1 (en) * 2004-08-24 2006-03-02 Ishikawa Muriel Y System and method related to improving an immune system
US20060116824A1 (en) * 2004-12-01 2006-06-01 Ishikawa Muriel Y System and method for modulating a humoral immune response
US20060182742A1 (en) * 2004-08-24 2006-08-17 Ishikawa Muriel Y System and method for magnifying a humoral immune response
US20060095211A1 (en) * 2003-12-05 2006-05-04 Searete Llc, A Limited Liability Corporation Of The State Of Delaware System and method for modulating a cell mediated immune response
US20060122783A1 (en) * 2004-08-24 2006-06-08 Ishikawa Muriel Y System and method for heightening a humoral immune response
US20060047437A1 (en) * 2004-08-25 2006-03-02 Ishikawa Muriel Y System and method for heightening an immune response
US20060047433A1 (en) * 2004-08-24 2006-03-02 Ishikawa Muriel Y System and method related to enhancing an immune system
GB0328363D0 (en) 2003-12-06 2004-01-14 Imp College Innovations Ltd Therapeutically useful molecules
GB0411773D0 (en) * 2004-05-26 2004-06-30 Avidex Ltd Method for the identification of polypeptides which bind to a given peptide mhc complex or cd 1-antigen complex
US8361794B2 (en) 2004-06-29 2013-01-29 Immunocore Limited Cells expressing a modified T cell receptor
US20060047439A1 (en) * 2004-08-24 2006-03-02 Searete Llc, A Limited Liability Corporation Of The State Of Delaware System and method for improving a humoral immune response
US20070198196A1 (en) * 2004-08-24 2007-08-23 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational systems and methods relating to ameliorating an immune system
US20070265818A1 (en) * 2004-08-24 2007-11-15 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational methods and systems for heightening cell-mediated immune response
US20070265819A1 (en) * 2004-08-24 2007-11-15 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational methods and systems for improving cell-mediated immune response
US20070196362A1 (en) * 2004-08-24 2007-08-23 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational methods and systems to bolster an immune response
US20070207492A1 (en) * 2004-08-24 2007-09-06 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational methods and systems to adjust a humoral immune response
MX2007003910A (es) * 2004-10-01 2007-06-07 Avidex Ltd Receptores de celulas t que contienen un enlace entre cadenas bisulfuro no nativo ligado a agentes terapeuticos.
KR20130105885A (ko) 2005-01-05 2013-09-26 에프-스타 비오테크놀로기쉐 포르슝스 운드 엔트비클룽스게스.엠.베.하. 상보성 결정부위와 다른 분자의 부위에서 처리된 결합성을 갖는 합성 면역글로불린 영역
GB0514779D0 (en) * 2005-07-19 2005-08-24 Celltech R&D Ltd Biological products
KR101441693B1 (ko) 2005-10-18 2014-09-25 내셔날 쥬이쉬 헬스 조건부 불멸화 장기 줄기 세포 및 상기 세포의 제조 및사용 방법
CA2651174A1 (en) * 2006-05-03 2007-11-15 Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services Chimeric t cell receptors and related materials and methods of use
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
AT503861B1 (de) * 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von t-zell-rezeptoren
ES2627223T3 (es) 2007-06-26 2017-07-27 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H Presentación de agentes de unión
EP2113255A1 (de) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Zytotoxisches Immunglobulin
SG190661A1 (en) 2008-05-16 2013-06-28 Taiga Biotechnologies Inc Antibodies and processes for preparing the same
JP5812861B2 (ja) 2008-08-28 2015-11-17 タイガ バイオテクノロジーズ，インク． Ｍｙｃの修飾物質、該ｍｙｃの修飾物質を使用する方法、およびｍｙｃを調節する薬剤を同定する方法
US8748103B2 (en) 2008-11-07 2014-06-10 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
US9365901B2 (en) 2008-11-07 2016-06-14 Adaptive Biotechnologies Corp. Monitoring immunoglobulin heavy chain evolution in B-cell acute lymphoblastic leukemia
US9528160B2 (en) 2008-11-07 2016-12-27 Adaptive Biotechnolgies Corp. Rare clonotypes and uses thereof
US9506119B2 (en) 2008-11-07 2016-11-29 Adaptive Biotechnologies Corp. Method of sequence determination using sequence tags
EP2719774B8 (de) 2008-11-07 2020-04-22 Adaptive Biotechnologies Corporation Verfahren zur Überwachung von Zuständen durch Sequenzanalyse
US8628927B2 (en) 2008-11-07 2014-01-14 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
HUE029424T2 (en) 2009-01-15 2017-02-28 Adaptive Biotechnologies Corp Adaptive immunity profiling and a method for producing monoclonal antibodies
EP2258719A1 (de) * 2009-05-19 2010-12-08 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Mehrfachziel-T-Zellen-Rezeptor
GB0908613D0 (en) 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
CN102482321B (zh) 2009-06-22 2015-06-17 安姆根有限公司 使用化学控制的氧化还原态重折叠蛋白质
RU2539032C2 (ru) 2009-06-25 2015-01-10 Фред Хатчинсон Кансэр Рисёч Сентер Способ измерения искусственного иммунитета
WO2010151688A2 (en) 2009-06-25 2010-12-29 Amgen Inc. Capture purification processes for proteins expressed in a non-mammalian system
US10385475B2 (en) 2011-09-12 2019-08-20 Adaptive Biotechnologies Corp. Random array sequencing of low-complexity libraries
AU2012325791B2 (en) 2011-10-21 2018-04-05 Adaptive Biotechnologies Corporation Quantification of adaptive immune cell genomes in a complex mixture of cells
ES2867924T3 (es) 2011-12-09 2021-10-21 Adaptive Biotechnologies Corp Diagnóstico de tumores malignos linfoides y detección de enfermedad residual mínima
US9499865B2 (en) 2011-12-13 2016-11-22 Adaptive Biotechnologies Corp. Detection and measurement of tissue-infiltrating lymphocytes
EP2823060B1 (de) 2012-03-05 2018-02-14 Adaptive Biotechnologies Corporation Festlegung von gepaarten immunrezeptorketten aus frequenzabgestimmten untereinheiten
DK2831276T3 (da) 2012-05-08 2016-08-01 Adaptive Biotechnologies Corp Sammensætninger og fremgangsmåde til at måle og kalibrere amplifikations-bias i multipleks-PCR-reaktioner
SG11201500429QA (en) 2012-07-20 2015-03-30 Taiga Biotechnologies Inc Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
US20160002731A1 (en) 2012-10-01 2016-01-07 Adaptive Biotechnologies Corporation Immunocompetence assessment by adaptive immune receptor diversity and clonality characterization
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
US9708657B2 (en) 2013-07-01 2017-07-18 Adaptive Biotechnologies Corp. Method for generating clonotype profiles using sequence tags
TWI714869B (zh) 2013-08-05 2021-01-01 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
AU2014352834B2 (en) 2013-11-22 2019-08-29 Fred Hutchinson Cancer Research Center Engineered high-affinity human T cell receptors
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
JP7060324B2 (ja) 2013-12-20 2022-04-26 ザ・ブロード・インスティテュート・インコーポレイテッド ネオ抗原ワクチンによる併用療法
AU2015227054A1 (en) 2014-03-05 2016-09-22 Adaptive Biotechnologies Corporation Methods using randomer-containing synthetic molecules
US20230027993A1 (en) 2014-03-05 2023-01-26 Autolus Limited Methods
US11385233B2 (en) 2015-03-05 2022-07-12 Autolus Limited Methods of depleting malignant T-cells
US20170066827A1 (en) * 2014-03-05 2017-03-09 Ucl Business Plc Chimeric antigen receptor
US10066265B2 (en) 2014-04-01 2018-09-04 Adaptive Biotechnologies Corp. Determining antigen-specific t-cells
US11390921B2 (en) 2014-04-01 2022-07-19 Adaptive Biotechnologies Corporation Determining WT-1 specific T cells and WT-1 specific T cell receptors (TCRs)
EP3132059B1 (de) 2014-04-17 2020-01-08 Adaptive Biotechnologies Corporation Quantifizierung von adaptiven immunzellgenomen in einer komplexen mischung von zellen
GB201408255D0 (en) 2014-05-09 2014-06-25 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
GB201411037D0 (en) 2014-06-20 2014-08-06 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL)
CA2966201A1 (en) 2014-10-29 2016-05-06 Adaptive Biotechnologies Corp. Highly-multiplexed simultaneous detection of nucleic acids encoding paired adaptive immune receptor heterodimers from many samples
EP3216801B1 (de) 2014-11-07 2020-01-01 Guangdong Xiangxue Life Sciences, Ltd. Löslicher heterodermischer t-zell-rezeptor sowie herstellungsverfahren und verwendung davon
US10246701B2 (en) 2014-11-14 2019-04-02 Adaptive Biotechnologies Corp. Multiplexed digital quantitation of rearranged lymphoid receptors in a complex mixture
AU2015353581A1 (en) 2014-11-25 2017-06-15 Adaptive Biotechnologies Corporation Characterization of adaptive immune response to vaccination or infection using immune repertoire sequencing
EP4636401A2 (de) 2014-12-19 2025-10-22 The Broad Institute, Inc. Verfahren zur profilierung des t-zell-rezeptor-repertoirs
WO2016100975A1 (en) 2014-12-19 2016-06-23 Massachsetts Institute Ot Technology Molecular biomarkers for cancer immunotherapy
HRP20211754T1 (hr) 2014-12-23 2022-03-04 Immatics Biotechnologies Gmbh Novi peptidi i kombinacije peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih rakova
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
ES2858306T3 (es) 2015-02-24 2021-09-30 Adaptive Biotechnologies Corp Método para determinar el estado de HLA mediante secuenciación del repertorio inmunitario
DK3388075T5 (da) 2015-03-27 2024-09-23 Immatics Biotechnologies Gmbh Hidtil ukendte peptider og kombination af peptider til anvendelse ved immunterapi mod forskellige tumorer
GB201505585D0 (en) 2015-03-31 2015-05-13 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
EP3277294B1 (de) 2015-04-01 2024-05-15 Adaptive Biotechnologies Corp. Verfahren zur identifizierung von menschlichen kompatiblen t-zell-rezeptoren spezifisch für ein antigen-ziel
GB201507030D0 (en) 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
GB201507719D0 (en) 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
MX2017014700A (es) 2015-05-20 2018-08-15 Broad Inst Inc Neoantigenos compartidos.
CN106279404A (zh) * 2015-05-20 2017-01-04 广州市香雪制药股份有限公司 一种可溶且稳定的异质二聚tcr
WO2016205749A1 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Novel crispr enzymes and systems
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
HRP20202019T1 (hr) 2015-07-01 2021-04-30 Immatics Biotechnologies Gmbh Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv raka jajnika i drugih malignih tumora
MA51531A (fr) 2015-07-06 2020-11-11 Immatics Biotechnologies Gmbh Nouveaux peptides et nouvelle combinaison de peptides à utiliser dans l'immunothérapie du cancer de l' oesophage et d'autres cancers
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
GB201516272D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
GB201516277D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR libraries
WO2017069958A2 (en) 2015-10-09 2017-04-27 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
WO2017075451A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
WO2017075478A2 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
WO2017075465A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
WO2017087708A1 (en) 2015-11-19 2017-05-26 The Brigham And Women's Hospital, Inc. Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
GB201522667D0 (en) 2015-12-22 2016-02-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
GB201602918D0 (en) 2016-02-19 2016-04-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
IL302705A (en) 2016-03-01 2023-07-01 Immatics Biotechnologies Gmbh Peptides, combinations of peptides, cell-based drugs for use in immunotherapy against bladder cancer and other types of cancer
GB201603987D0 (en) 2016-03-08 2016-04-20 Immatics Biotechnologies Gmbh Uterine cancer treatments
DK3430037T3 (da) 2016-03-16 2022-11-21 Immatics Biotechnologies Gmbh Transficerede t-celler og t-cellereceptorer til anvendelse i immunterapi mod cancere
CN116731156A (zh) 2016-03-16 2023-09-12 伊玛提克斯生物技术有限公司 用于癌症免疫治疗的转染t细胞和t细胞受体
CR20180530A (es) 2016-04-06 2019-03-11 Immatics Biotechnologies Gmbh Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra la leucemia mieloide aguda (lma) y otros tipos de cancer
ES2991142T3 (es) 2016-04-08 2024-12-02 Adaptimmune Ltd Receptores de linfocitos T
CN116239669A (zh) * 2016-04-08 2023-06-09 艾达普特免疫有限公司 T细胞受体
ES2914648T3 (es) * 2016-04-08 2022-06-15 Immunocore Ltd Receptores de células T
HRP20211493T1 (hr) 2016-04-08 2022-01-21 Adaptimmune Limited Receptori t stanica
EP3446119A1 (de) 2016-04-18 2019-02-27 The Broad Institute Inc. Verbesserte hla-epitopvorhersage
PT3464380T (pt) 2016-06-02 2025-02-06 Immunocore Ltd Regime de dosagem para proteína de fusão de tcr específico de gp100 - scfv anti-cd3
WO2018035364A1 (en) 2016-08-17 2018-02-22 The Broad Institute Inc. Product and methods useful for modulating and evaluating immune responses
TW202304970A (zh) 2016-08-26 2023-02-01 德商英麥提克生物技術股份有限公司 用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架
WO2018049025A2 (en) 2016-09-07 2018-03-15 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses
US10428325B1 (en) 2016-09-21 2019-10-01 Adaptive Biotechnologies Corporation Identification of antigen-specific B cell receptors
WO2018064208A1 (en) 2016-09-28 2018-04-05 The Broad Institute, Inc. Systematic screening and mapping of regulatory elements in non-coding genomic regions, methods, compositions, and applications thereof
WO2018067991A1 (en) 2016-10-07 2018-04-12 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
US12227578B2 (en) 2016-11-11 2025-02-18 The Broad Institute, Inc. Modulation of intestinal epithelial cell differentiation, maintenance and/or function through T cell action
AU2017367730A1 (en) 2016-12-02 2019-06-06 Taiga Biotechnologies, Inc. Nanoparticle formulations
WO2018102795A2 (en) * 2016-12-02 2018-06-07 University Of Southern California Synthetic immune receptors and methods of use thereof
WO2018140391A1 (en) 2017-01-24 2018-08-02 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
WO2018138257A1 (en) 2017-01-27 2018-08-02 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
WO2018143454A1 (ja) 2017-02-06 2018-08-09 国立研究開発法人国立がん研究センター 新規ｔ細胞受容体
SI3580561T1 (sl) 2017-02-12 2024-04-30 Biontech Us Inc. Metode, osnovane na hla, in njihove sestave ter uporabe
US11963966B2 (en) 2017-03-31 2024-04-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating ovarian tumors
US11913075B2 (en) 2017-04-01 2024-02-27 The Broad Institute, Inc. Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
EA201992416A1 (ru) 2017-04-10 2020-02-25 Имматикс Байотекнолоджиз Гмбх Пептиды и комбинации пептидов для применения в иммунотерапии лейкозов и других видов рака
TW201841934A (zh) 2017-04-10 2018-12-01 德商英麥提克生物技術股份有限公司 用於治療癌症免疫治療的新穎肽及其肽組合物
AU2018251839B2 (en) 2017-04-10 2022-06-30 Immatics Biotechnologies Gmbh Peptides and combination thereof for use in the immunotherapy against cancers
WO2018191553A1 (en) 2017-04-12 2018-10-18 Massachusetts Eye And Ear Infirmary Tumor signature for metastasis, compositions of matter methods of use thereof
MX2019012398A (es) 2017-04-18 2020-09-25 Broad Inst Inc Composiciones para detectar secreciones y metodos de uso.
US12226479B2 (en) 2017-05-11 2025-02-18 The General Hospital Corporation Methods and compositions of use of CD8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof
WO2018213726A1 (en) 2017-05-18 2018-11-22 The Broad Institute, Inc. Systems, methods, and compositions for targeted nucleic acid editing
GB201709203D0 (en) * 2017-06-09 2017-07-26 Autolus Ltd Antigen-binding domain
WO2018232195A1 (en) 2017-06-14 2018-12-20 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
EP4316597A3 (de) 2017-07-07 2024-11-06 immatics biotechnologies GmbH Neuartige peptide und kombination aus peptiden zur verwendung in der immuntherapie gegen lungenkrebs, einschliesslich nsclc, sclc und andere krebsarten
US10800823B2 (en) 2017-07-07 2020-10-13 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers
WO2019014581A1 (en) 2017-07-14 2019-01-17 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF A CYTOTOXIC LYMPHOCYTE
EP4026554A1 (de) 2017-08-03 2022-07-13 Taiga Biotechnologies, Inc. Verfahren und zusammensetzungen zur behandlung von melanom
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
KR20200066616A (ko) 2017-09-21 2020-06-10 더 브로드 인스티튜트, 인코퍼레이티드 표적화된 핵산 편집을 위한 시스템, 방법 및 조성물
KR20250029294A (ko) 2017-09-22 2025-03-04 우시 바이올로직스 아일랜드 리미티드 신규한 이중특이적 cd3/cd19 폴리펩티드 복합체
EA202090812A1 (ru) * 2017-09-22 2020-08-07 Уси Байолоджикс Аэлэнд Лимитед Новые биспецифические полипептидные комплексы
US12043870B2 (en) 2017-10-02 2024-07-23 The Broad Institute, Inc. Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
WO2019069125A1 (en) 2017-10-06 2019-04-11 Oslo Universitetssykehus Hf CHIMERIC ANTIGEN RECEPTORS
KR102823603B1 (ko) 2017-10-12 2025-06-23 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 면역요법을 위한 t 세포 수용체
WO2019084055A1 (en) 2017-10-23 2019-05-02 Massachusetts Institute Of Technology CLASSIFICATION OF GENETIC VARIATION FROM UNICELLULAR TRANSCRIPTOMS
US12171783B2 (en) 2017-11-13 2024-12-24 The Broad Institute, Inc. Methods and compositions for targeting developmental and oncogenic programs in H3K27M gliomas
EP3710039A4 (de) 2017-11-13 2021-08-04 The Broad Institute, Inc. Verfahren und zusammensetzungen zur behandlung von krebs durch targeting des clec2d-klrb1-wegs
JP2021503885A (ja) 2017-11-22 2021-02-15 アイオバンス バイオセラピューティクス，インコーポレイテッド 末梢血からの末梢血リンパ球（ｐｂｌ）の拡大培養
US11254980B1 (en) 2017-11-29 2022-02-22 Adaptive Biotechnologies Corporation Methods of profiling targeted polynucleotides while mitigating sequencing depth requirements
US20210115106A1 (en) * 2017-12-07 2021-04-22 Janux Therapeutics, Inc. Modified t cell receptors
US11994512B2 (en) 2018-01-04 2024-05-28 Massachusetts Institute Of Technology Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
US20210041435A1 (en) * 2018-01-31 2021-02-11 Tohoku University Method for regulating antigen-specific mhc expression
DE102018107224A1 (de) 2018-02-21 2019-08-22 Immatics Biotechnologies Gmbh Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
AU2019249215B2 (en) 2018-04-06 2026-02-19 The Regents Of The University Of California Methods of treating EGFRvIII expressing glioblastomas
EP3773633A4 (de) 2018-04-06 2022-01-26 The Regents of The University of California Verfahren zur behandlung von glioblastomen
US11957695B2 (en) 2018-04-26 2024-04-16 The Broad Institute, Inc. Methods and compositions targeting glucocorticoid signaling for modulating immune responses
TW202016131A (zh) 2018-05-16 2020-05-01 德商英麥提克生物技術股份有限公司 用於抗癌免疫治療的肽
WO2019232542A2 (en) 2018-06-01 2019-12-05 Massachusetts Institute Of Technology Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
US12036240B2 (en) 2018-06-14 2024-07-16 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
US10925947B2 (en) 2018-06-29 2021-02-23 Immatics Biotechnologies Gmbh A*03 restricted peptides for use in immunotherapy against cancers and related methods
TW202019955A (zh) 2018-07-31 2020-06-01 德商英麥提克生物技術股份有限公司 B*07 限制肽和肽組合的抗癌免疫治療和相關方法
US20210324357A1 (en) 2018-08-20 2021-10-21 The Brigham And Women's Hospital, Inc. Degradation domain modifications for spatio-temporal control of rna-guided nucleases
US12460244B2 (en) 2018-08-20 2025-11-04 The Broad Institute, Inc. Inhibitors of RNA-guided nuclease activity and uses thereof
WO2020068304A2 (en) 2018-08-20 2020-04-02 The Broad Institute, Inc. Inhibitors of rna-guided nuclease target binding and uses thereof
US11945850B2 (en) 2018-09-17 2024-04-02 Immatics Biotechnologies Gmbh B*44 restricted peptides for use in immunotherapy against cancers and related methods
TW202024121A (zh) 2018-09-18 2020-07-01 德商英麥提克生物技術股份有限公司 A*01 限制肽和肽組合物在抗癌免疫治療中的用途和相關方法
WO2020072700A1 (en) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
WO2020081730A2 (en) 2018-10-16 2020-04-23 Massachusetts Institute Of Technology Methods and compositions for modulating microenvironment
WO2020092455A2 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Car t cell transcriptional atlas
EP3876956A4 (de) 2018-11-08 2022-12-28 The Regents of The University of California Systeme und verfahren zum targeting von krebszellen
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
TW202039535A (zh) 2018-12-18 2020-11-01 德商英麥提克生物技術股份有限公司 B*08限制肽和肽組合物抗癌免疫治療和相關方法
AU2019404547B2 (en) 2018-12-21 2025-01-30 Biontech Us Inc. Method and systems for prediction of HLA class II-specific epitopes and characterization of CD4+ T cells
US11739156B2 (en) 2019-01-06 2023-08-29 The Broad Institute, Inc. Massachusetts Institute of Technology Methods and compositions for overcoming immunosuppression
US20220133795A1 (en) 2019-03-01 2022-05-05 Iovance Biotherapeutics, Inc. Expansion of Tumor Infiltrating Lymphocytes From Liquid Tumors and Therapeutic Uses Thereof
US20220154282A1 (en) 2019-03-12 2022-05-19 The Broad Institute, Inc. Detection means, compositions and methods for modulating synovial sarcoma cells
WO2020191079A1 (en) 2019-03-18 2020-09-24 The Broad Institute, Inc. Compositions and methods for modulating metabolic regulators of t cell pathogenicity
US20220195397A1 (en) * 2019-04-04 2022-06-23 Shanghai Pharmaceuticals Holding Co., Ltd. Immune cell containing tumor antigen recognition receptor and application thereof
WO2020210231A1 (en) 2019-04-08 2020-10-15 Taiga Biotechnologies, Inc. Compositions and methods for the cry opreservation of immune cells
CN114072166A (zh) 2019-05-14 2022-02-18 泰加生物工艺学公司 用于治疗t细胞耗竭的组合物和方法
WO2020236967A1 (en) 2019-05-20 2020-11-26 The Broad Institute, Inc. Random crispr-cas deletion mutant
WO2020243371A1 (en) 2019-05-28 2020-12-03 Massachusetts Institute Of Technology Methods and compositions for modulating immune responses
US20220282333A1 (en) 2019-08-13 2022-09-08 The General Hospital Corporation Methods for predicting outcomes of checkpoint inhibition and treatment thereof
US12421557B2 (en) 2019-08-16 2025-09-23 The Broad Institute, Inc. Methods for predicting outcomes and treating colorectal cancer using a cell atlas
US20220298501A1 (en) 2019-08-30 2022-09-22 The Broad Institute, Inc. Crispr-associated mu transposase systems
CA3149939A1 (en) 2019-09-06 2021-03-11 Stephen J. Demarest Proteins comprising t-cell receptor constant domains
US12297426B2 (en) 2019-10-01 2025-05-13 The Broad Institute, Inc. DNA damage response signature guided rational design of CRISPR-based systems and therapies
US12394502B2 (en) 2019-10-02 2025-08-19 The General Hospital Corporation Method for predicting HLA-binding peptides using protein structural features
US11981922B2 (en) 2019-10-03 2024-05-14 Dana-Farber Cancer Institute, Inc. Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
US12195725B2 (en) 2019-10-03 2025-01-14 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity
US11793787B2 (en) 2019-10-07 2023-10-24 The Broad Institute, Inc. Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
CN112251452A (zh) * 2019-10-22 2021-01-22 上海斯丹赛生物技术有限公司 Til/tcr-t细胞治疗平台
US11844800B2 (en) 2019-10-30 2023-12-19 Massachusetts Institute Of Technology Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
US12195723B2 (en) 2019-11-08 2025-01-14 The Broad Institute, Inc. Engineered antigen presenting cells and uses thereof
US20220389075A1 (en) 2019-11-12 2022-12-08 A2 Biotherapeutics, Inc. Engineered t cell receptors and uses thereof
US11865168B2 (en) 2019-12-30 2024-01-09 Massachusetts Institute Of Technology Compositions and methods for treating bacterial infections
US12165747B2 (en) 2020-01-23 2024-12-10 The Broad Institute, Inc. Molecular spatial mapping of metastatic tumor microenvironment
WO2021190580A1 (en) * 2020-03-26 2021-09-30 Wuxi Biologics (Shanghai) Co., Ltd. Bispecific polypeptide complexes, compositions, and methods of preparation and use
DE102020125457A1 (de) 2020-09-29 2022-03-31 Immatics Biotechnologies Gmbh Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
DE102020125465A1 (de) 2020-09-29 2022-03-31 Immatics Biotechnologies Gmbh Amidierte Peptide und ihre deamidierten Gegenstücke, die durch nicht-HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
TW202229312A (zh) 2020-09-29 2022-08-01 德商英麥提克生物技術股份有限公司 由非ｈｌａ－ａ*０２顯露以用於不同類型癌症之免疫治療的醯胺化肽及其脫醯胺化對應物
EP4232071A4 (de) 2020-10-23 2024-08-28 Asher Biotherapeutics, Inc. Fusionen mit cd8-antigenbindenden molekülen zur modulation der immunzellenfunktion
CN112239495B (zh) * 2020-10-29 2022-04-12 上海药明生物技术有限公司 稳定的tcr结构及应用
TW202241925A (zh) 2021-01-15 2022-11-01 德商英麥提克生物技術股份有限公司 用於不同類型癌症免疫治療的ｈｌａ展示肽
US12218561B2 (en) 2021-02-25 2025-02-04 Regal Beloit America, Inc. Electric machine assembly having a rotor frame to provide cooling
US20240150711A1 (en) 2021-03-01 2024-05-09 Dana-Farber Cancer Institute, Inc. Personalized redirection and reprogramming of t cells for precise targeting of tumors
US20250205324A1 (en) 2022-03-31 2025-06-26 Enterome S.A. Antigenic peptides for prevention and treatment of cancer
TW202417476A (zh) 2022-08-18 2024-05-01 英商英美偌科有限公司 Ｔ細胞受體及其融合蛋白
WO2024047642A1 (en) * 2022-08-30 2024-03-07 Clonal Ltd Methods for detection of ovarian cancer
EP4598949A1 (de) 2022-10-07 2025-08-13 The General Hospital Corporation Verfahren und zusammensetzungen zur hochdurchsatzentdeckung von auf peptid-mhc abzielenden bindungsproteinen
WO2024098024A1 (en) 2022-11-04 2024-05-10 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
WO2024124044A1 (en) 2022-12-07 2024-06-13 The Brigham And Women’S Hospital, Inc. Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
WO2024192141A1 (en) 2023-03-13 2024-09-19 Dana-Farber Cancer Institute, Inc. Treatment of cancers having a drug-resistant mesenchymal cell state
WO2024226838A2 (en) 2023-04-25 2024-10-31 The Brigham And Women's Hospital, Inc. Treatment of autoimmune diseases having a pathogenic t cell state
CN121532421A (zh) * 2023-06-21 2026-02-13 北京可瑞生物科技有限公司 经修饰的tcr恒定区及其在tcr融合蛋白中的用途
WO2025040598A2 (en) 2023-08-18 2025-02-27 Immatics Biotechnologies Gmbh Peptides displayed by mhc for use in immunotherapy against different types of cancer
WO2025059533A1 (en) 2023-09-13 2025-03-20 The Broad Institute, Inc. Crispr enzymes and systems
WO2025097055A2 (en) 2023-11-02 2025-05-08 The Broad Institute, Inc. Compositions and methods of use of t cells in immunotherapy
WO2025117544A1 (en) 2023-11-29 2025-06-05 The Broad Institute, Inc. Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof
WO2025224084A1 (en) 2024-04-22 2025-10-30 Engimmune Therapeutics Ag Proteins comprising t cell receptor constant domains

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080840A (en) * 1992-01-17 2000-06-27 Slanetz; Alfred E. Soluble T cell receptors
US5747654A (en) * 1993-06-14 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Recombinant disulfide-stabilized polypeptide fragments having binding specificity
WO1996021028A2 (en) * 1995-01-03 1996-07-11 Procept, Inc. Soluble heterodimeric t cell receptors and their antibodies
AU758949B2 (en) * 1998-05-19 2003-04-03 Avidex Limited Multivalent T cell receptor complexes
EP1421115B1 (de) * 2001-08-31 2005-03-02 Avidex Limited Löslicher t zell rezeptor

Also Published As

Publication number Publication date
EP1594896A1 (de) 2005-11-16
CA2516702A1 (en) 2004-09-02
US7666604B2 (en) 2010-02-23
WO2004074322A1 (en) 2004-09-02
ZA200506516B (en) 2006-04-26
CN1745099A (zh) 2006-03-08
CA2516702C (en) 2012-11-27
DE60319745T2 (de) 2009-04-23
CN100528897C (zh) 2009-08-19
AU2003254443A1 (en) 2004-09-09
DE60319745D1 (de) 2008-04-24
US20070082362A1 (en) 2007-04-12
AU2003254443B2 (en) 2009-03-26
EP1594896B1 (de) 2008-03-12
JP4478034B2 (ja) 2010-06-09
NZ541596A (en) 2008-05-30
GB0304068D0 (en) 2003-03-26
JP2007527191A (ja) 2007-09-27

Similar Documents

Publication Publication Date Title
ATE388964T1 (de) Modifizierter löslicher t-zellen-rezeptor
NO20041325L (no) Substanser
DE602005022595D1 (de) Einen modifizierten t-zellen-rezeptor exprimierende zellen
NO20092052L (no) Antistoffer og immunkonjugater, og anvendelser derav
NO20083397L (no) Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse
MA30153B1 (fr) Anticorps anti-ox40l et methodes correspondantes
DK1940918T3 (da) Dimercaptanterminerede polythioetherpolymerer og fremgangsmåder til at fremstille og anvende samme
CY1110579T1 (el) Η λειτουργια ενος υποδοχεα απτοσφαιρινης-αιμοσφαιρινης και οι χρησεις αυτου
EP3835322A3 (de) Anti-b7-h3-antikörper und antikörperarzneimittelkonjugate
SG170091A1 (en) Anti-5t4 antibodies and uses thereof
DE69918946D1 (de) Rezeptoren für il-18
MX2009007145A (es) Conjugados de polimero con factor viii y factor de von willebrand que tienen una ligadura liberable.
CY1107133T1 (el) Κυκλικοι ανταγωνιστες των υποδοχεων c5a και συζευγμενοι με πρωτεϊνη g υποδοχεις
EP1771205A4 (de) Neuartige antigen-bindende polypeptide und ihre verwendungen
DK1316801T3 (da) Sammensætninger og fremgangsmåder til detektion og behandling af sygdomme og tilstande, som er relateret til kemokinreceptorer
DK1368274T3 (da) Indstillelig sadel
WO2023168455A3 (en) Anti-lilrb1/2 antibodies and uses thereof
ATE417833T1 (de) Triazinderivate mit carbamatfunktion
EA200702193A1 (ru) Гликозилирование белков
DE602006007967D1 (de) Gegen das gemeinsame epitop von mutierten p53 gerichtete humane synthetische einzelkettenantikörper und anwendungen davon
DE602006020037D1 (de) Spezifisch an vygfvracl-hla-a24 bindende t-zellen-rezeptoren
DK1864131T3 (da) Naturlig ligand af G protein koblet receptor RCC356 og anvendelser deraf
MX2022010239A (es) Poblaciones de linfocitos t gamma delta ex vivo.
BRPI0507019A (pt) composição, uso de anticorpo, anticorpo, uso de msrv/herv-w env-su
DE60325552D1 (de) Alkoxysilylfunktionelle materialien auf siliconbasis

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties